wsxc12567
(Account not Activated)


Registration Date: 04-01-2019
Date of Birth: Not Specified
Local Time: 04-20-2024 at 04:22 AM
Status: Offline

wsxc12567's Forum Info
Joined: 04-01-2019
Last Visit: 04-01-2019, 01:23 AM
Total Posts: 0 (0 posts per day | 0 percent of total posts)
Total Threads: 0 (0 threads per day | 0 percent of total threads)
Time Spent Online: 4 Minutes, 41 Seconds
Members Referred: 0
  
Additional Info About wsxc12567
Bio: 4-hydroxyisoleucine
4-hydroxyisoleucine (Fenugreek extract)
Latin Name: Trigonella foenum-gracum L.
Active ingredient: 4-hydroxyisoleucine
Purity: 20%
Fenugreek’s most well-known compound is 4-hydroxyisoleucine, which works to normalize glucose metabolism.

4-Hydroxyisoleucine (HIL) from fenugreek (Trigonella foenum-graecum) seeds is a potential insulinotropic (anti-diabetic) and anti-obesity amino acid. HIL stimulates glucose-dependent insulin secretion from pancreatic cells. HIL activates insulin receptor substrate-associated phosphoinositide 3 (PI3) kinase activity. HIL reduces plasma levels of triglycerides, free fatty acids and cholesterol.

With CAS number 55399-93-4, and the popular specifications available on the market are 20% 4-hydroxyisoleucine and 40% 4-hydroxyisoleucine. The 4-hydroxyisoleucine help stimulate the secretion of insulin from your pancreas, reduce insulin resistance, and decrease blood sugar levels in diabetes patients. It also helps to enhance the glucose tolerance and reduces the amount of cholesterol efficiently.
AppearanceBrown yellow fine powder with characteristic odorVisual
IdentificationPasses all criteria testsHPLC(Aidu Criteria)
Assay(4-Hydroxy-isoleucine)≥20.0%HPLC(Aidu Criteria)
Loss On Drying≤5.0%USP〈731〉
Ash≤5.0%C561
Sieve80 MeshUSP〈786〉
Heavy Metals≤10 mg/kgUSP〈231〉Method II
Pb≤1.5 mg/kgICP-MS
As≤1.0 mg/kgICP-MS
Hg≤0.5 mg/kgICP-MS
Cd≤0.5 mg/kgICP-MS
Residual Solvent≤5,000 mg/kgGC
Pesticide ResidueMeet USP〈561〉USP〈561〉wholesale Enhance Libido Supplement
website:http://www.aidubio.com/nature-supplement/enhance-libido-supplement/
Sex: Undisclosed